EMEA-001220-PIP01-11-M10 - paediatric investigation plan

Baricitinib

Key facts

• Invented name:
  Olumiant
• Active Substance:
  Baricitinib
• Therapeutic area:
  Musculoskeletal and connective tissue disorders
• Decision number:
  P/0117/2024
• PIP number:
  EMEA-001220-PIP01-11-M10
• Pharmaceutical form(s):
  • Oral suspension
  • Film-coated tablet
• Condition(s) / indication(s):
  Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  12/04/2024

Decision

P/0117/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M10)

AdoptedReference Number: EMA/114607/2024